Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,871,850
  • Shares Outstanding, K 37,037
  • Annual Sales, $ 199,610 K
  • Annual Income, $ -17,480 K
  • EBIT $ 28 M
  • EBITDA $ 47 M
  • 60-Month Beta 0.07
  • Price/Sales 7.35
  • Price/Cash Flow 348.76
  • Price/Book 37.82

Options Overview Details

View History
  • Implied Volatility 91.51% (-3.49%)
  • Historical Volatility 52.22%
  • IV Percentile 65%
  • IV Rank 57.26%
  • IV High 122.86% on 03/11/25
  • IV Low 49.50% on 08/29/25
  • Expected Move (DTE 2) 2.04 (4.12%)
  • Put/Call Vol Ratio 1.31
  • Today's Volume 383
  • Volume Avg (30-Day) 1,082
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 33,265
  • Open Int (30-Day) 29,136
  • Expected Range 47.51 to 51.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.40
  • Number of Estimates 3
  • High Estimate 0.43
  • Low Estimate 0.36
  • Prior Year 0.25
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.61 +22.80%
on 01/30/26
50.91 -2.04%
on 02/18/26
+1.97 (+4.11%)
since 01/16/26
3-Month
36.95 +34.97%
on 11/20/25
54.85 -9.08%
on 01/07/26
+10.14 (+25.52%)
since 11/18/25
52-Week
20.85 +139.18%
on 04/09/25
54.85 -9.08%
on 01/07/26
+19.30 (+63.13%)
since 02/18/25

Most Recent Stories

More News
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 49.87 (-1.33%)
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber...

HROW : 49.87 (-1.33%)
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to  the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based...

HROW : 49.87 (-1.33%)
Harrow to Present at Two Investor Conferences in December

NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate...

HROW : 49.87 (-1.33%)
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition...

HROW : 49.87 (-1.33%)
Harrow: Q3 Earnings Snapshot

Harrow: Q3 Earnings Snapshot

HROW : 49.87 (-1.33%)
Harrow Announces Third Quarter 2025 Financial Results

Third-Quarter 2025 and Recent Selected Highlights:  Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted...

HROW : 49.87 (-1.33%)
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 49.87 (-1.33%)
Craig-Hallum Sticks to Their Buy Rating for Harrow Health (HROW)

In a report released today, Chase Knickerbocker from Craig-Hallum reiterated a Buy rating on Harrow Health, with a price target of $64.00. The company’s shares closed last Friday at $37.48.Elevate Your...

HROW : 49.87 (-1.33%)
Craig-Hallum Sticks to Their Buy Rating for Harrow Health (HROW)

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Harrow Health. The company’s shares closed last Friday at $45.43.Elevate Your Investing Strategy: Take advantage...

HROW : 49.87 (-1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Harrow Inc. is an eyecare pharmaceutical company. It engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products principally for the U.S. market. Harrow Inc., formerly known as Harrow Health Inc., is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 56.37
2nd Resistance Point 53.53
1st Resistance Point 52.03
Last Price 49.87
1st Support Level 47.70
2nd Support Level 44.86
3rd Support Level 43.36

See More

52-Week High 54.85
Last Price 49.87
Fibonacci 61.8% 41.86
Fibonacci 50% 37.85
Fibonacci 38.2% 33.84
52-Week Low 20.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar